Ayati Devices raises Rs 15 Cr led by Inflexor

Bengaluru-based medical technology startup Ayati Devices has raised Rs 15 crore, about $1.5 Mn, in a pre-Series A round led by Inflexor Ventures. No other investor is named in the announcement, and no valuation is disclosed. The stated use of funds is to accelerate commercialisation, expand in domestic and international markets, strengthen manufacturing and increase investment in research and artificial intelligence.

Ayati was founded in 2019 by Nishant Kathpal, the only founder named, and was incubated at IIT Bombay’s Society for Innovation and Entrepreneurship. It builds diagnostic technology for diabetic foot complications and peripheral vascular disease, with a portfolio of portable point-of-care devices intended to move early screening out of tertiary hospitals. The report lists Vibrasense for vibration perception threshold testing, Vibrasense+T for vibration and thermal testing, Vasosense for peripheral artery disease screening, Angiocam for real-time tissue perfusion imaging, and a PODIA Trolley sold on a pay-per-test basis.

On traction, the company claims deployment across 30 countries with more than 10,000 devices placed and clinical deployments at healthcare institutions. Its website reports more than 1 million screenings enabled. A clinical evaluation involving 562 people with type 2 diabetes compared Vibrasense-based vibration perception threshold testing with conventional biothesiometry and nerve conduction studies for screening diabetic peripheral neuropathy. The report does not give the result of that study, and it carries no revenue figure, no valuation and no quote from the founder or the investor, so nothing about unit economics can be read from it.

What the round does say is worth noting plainly. This is a company founded in 2019 taking a pre-Series A in 2026, roughly seven years in. Hardware and medical devices run on a regulatory and clinical clock that software does not, and the stage label reflects where the commercial ramp sits rather than how long the company has existed. The use of funds reads as a list of things not yet done: commercialise, expand, manufacture at scale.

For Indian deeptech that is the honest signal. A Rs 15 Cr domestic cheque into a seven-year-old device company is patient capital by the standards of the current market, but it is still a small round, and the absence of any disclosed revenue or valuation means the market is being asked to take the device count on trust.